GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Dyne Therapeutics Inc.
The stock of Dyne Therapeutics, a biotech developing drugs to treat rare muscle diseases, reflects the potential of its innovative platform. The price chart is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - Pharma neurology
Dyne is a biotech company specializing in the treatment of rare muscle diseases. Its business consists of this segment alone. We classify it in the Pharmaceutical Neurology sector, and the chart below shows the general dynamics of biotech companies, where value is determined by the success of clinical data.
Broad Market Index - GURU.Markets
Dyne Therapeutics is a biotech company developing treatments for rare muscle diseases through targeted drug delivery to muscle tissue. It is a component of the GURU.Markets index. The chart below represents the market. See how Dyne shares compare to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
DYN - Daily change in the company's share price Dyne Therapeutics Inc.
The daily price change of Dyne Therapeutics, a biopharmaceutical company, reflects the extreme volatility of the biotech sector. change_co measures the reaction to clinical trial data. This metric is the basis for analyzing high-risk pharmaceutical assets on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma neurology
Dyne Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with DYN, which focuses on treating muscle diseases, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Dyne is a biopharmaceutical company developing treatments for rare muscle diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Dyne's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Dyne Therapeutics Inc.
Dyne is a biotech company working on treatments for neurological diseases. Its shares represent a venture capital bet on scientific success. Their high volatility, driven by expectations, contributes to the complex and multifaceted dynamics of the entire stock market.
Annual dynamics of market capitalization of the market segment - Pharma neurology
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing a new class of drugs for the treatment of rare muscle diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Dyne Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Dyne Therapeutics Inc.
Dyne, a biotech company developing drugs to treat rare muscle diseases, has sharp monthly fluctuations reflecting news about clinical trials of its platform.
Monthly dynamics of market capitalization of the market segment - Pharma neurology
This chart reflects the dynamics of the biotech sector. For Dyne, with its innovative platform for treating muscle diseases, it's the backdrop. Its movements demonstrate how positive data from early clinical trials can create high expectations for the entire niche.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Dyne Therapeutics is a biotech company developing treatments for rare muscle diseases. Its value depends almost entirely on progress in clinical trials. Its shares can experience explosive gains or catastrophic declines on news, with no correlation to the monthly fluctuations of the broader market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Dyne Therapeutics Inc.
Dyne Therapeutics is a clinical-stage biotech company developing drugs to treat rare muscle diseases. Its weekly stock price, like that of other biotechs, is entirely dependent on news about the progress of clinical trials. Positive data can trigger explosive price growth.
Weekly dynamics of market capitalization of the market segment - Pharma neurology
Dyne, as a clinical-stage biotech, lives in its own universe. Its weekly performance is 100% dependent on clinical trial news, not on general pharmaceutical industry trends. The chart clearly demonstrates these sharp, sector-neutral ups and downs, typical of biotechs on the cusp of breakthroughs.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. Its shares are driven by news of clinical trials. The chart clearly shows how much its performance is detached from the market and driven by scientific data.
Market capitalization of the company, segment and market as a whole
DYN - Market capitalization of the company Dyne Therapeutics Inc.
Dyne Therapeutics' market capitalization dynamics reflect investor expectations for its platform for treating rare muscle diseases. As a clinical-stage company, its valuation depends entirely on research results. Sharp movements in the chart reflect the market's reaction to any data that could confirm or refute the potential of its technology.
DYN - Share of the company's market capitalization Dyne Therapeutics Inc. within the market segment - Pharma neurology
Dyne Therapeutics is a biotech company seeking to capture market share in rare muscle diseases. Its market cap is based on the potential of its FORCE platform, which enables precise drug delivery to muscle tissue.
Market capitalization of the market segment - Pharma neurology
The chart below shows the overall value of the biotech sector. Dyne Therapeutics is developing a new generation of drugs to treat rare muscle diseases. Its platform aims to improve drug delivery to muscle tissue. The potential of this market is enormous, and Dyne is at the forefront of this complex scientific challenge.
Market capitalization of all companies included in a broad market index - GURU.Markets
Dyne Therapeutics is developing a platform for delivering drugs to muscle tissue to treat rare muscle diseases. Its market cap reflects the hope for a breakthrough in this complex field. The chart below shows the economic weight of biotech companies with unique technologies.
Book value capitalization of the company, segment and market as a whole
DYN - Book value capitalization of the company Dyne Therapeutics Inc.
Dyne Therapeutics' book value is derived from its equity and its FORCE scientific platform, which is designed to create antibody conjugates for the treatment of rare muscle diseases. The chart tells the story of a biotech company whose goal is to prove the efficacy of its unique technology in the clinic, turning its investment into a valuable intangible asset.
DYN - Share of the company's book capitalization Dyne Therapeutics Inc. within the market segment - Pharma neurology
Dyne Therapeutics develops drugs to treat muscle diseases. The chart shows its share of actual R&D assets. These are its laboratories where a platform for delivering drugs directly to muscle tissue is being developed, opening up new treatment options.
Market segment balance sheet capitalization - Pharma neurology
Dyne Therapeutics, Inc. is a clinical-stage biotech company, which accounts for its low capital intensity. Its value lies in its platform for creating conjugates for the treatment of muscle diseases, not in its manufacturing facilities. Compared to the pharmaceutical sector, its "light" balance sheet is typical of R&D companies.
Book value of all companies included in the broad market index - GURU.Markets
Dyne Therapeutics' assets represent research capital focused on developing a new class of drugs for the treatment of rare muscle diseases. The company's balance sheet reflects the value of its unique platform, which combines antibodies with small interfering RNA. The chart shows the resources invested in this cutting-edge gene therapy.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Dyne Therapeutics Inc.
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. Its market value is a pure valuation of its scientific platform and the potential of its drug candidates. The gap with book value on the chart reflects investor expectations for clinical success.
Market to book capitalization ratio in a market segment - Pharma neurology
Dyne Therapeutics develops drugs to treat rare muscle diseases. Its value lies in its unique drug delivery platform for muscle tissue. This chart illustrates the enormous premium investors are paying for the potential of this breakthrough technology, not just its modest tangible assets.
Market to book capitalization ratio for the market as a whole
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. Its market capitalization is based entirely on the potential of its scientific platform. The chart demonstrates the high premium the market is paying for the hope of a breakthrough in the treatment of severe genetic diseases.
Debts of the company, segment and market as a whole
DYN - Company debts Dyne Therapeutics Inc.
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. Its innovative platform requires significant investment to conduct preclinical and clinical trials. This chart shows how the company raises capital to fund its research and development efforts toward new drugs.
Market segment debts - Pharma neurology
Dyne Therapeutics is a biotech company developing treatments for rare muscle diseases. Being in the clinical stage, it requires significant investment in research. This chart shows the company's chosen funding path for its innovative platform and how its financing strategy compares to the standard biotech equity-based model.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Dyne Therapeutics Inc.
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. This chart shows its financial position at the clinical stage. The absence of debt and reliance on equity are typical of companies whose value is based solely on the potential of their innovative scientific platform and success in clinical trials.
Market segment debt to market segment book capitalization - Pharma neurology
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. The chart reflects the debt burden in a sector where scientific research requires massive investments with uncertain outcomes. It helps understand how Dyne's financial strategy balances the high risks and long-term nature of development in this field.
Debt to book value of all companies in the market
Dyne Therapeutics, a biotech company, operates by the laws of science, not debt markets. The chart reflects the overall debt burden for the entire economy. It emphasizes that for companies like Dyne, the key is not access to credit, but successful clinical trials, which open access to equity capital.
P/E of the company, segment and market as a whole
P/E - Dyne Therapeutics Inc.
For Dyne Therapeutics, a biotech developing drugs to treat muscle diseases, this chart represents a sign of hope. Its potential profit valuation is extremely high, as investors see a huge need for effective treatments for these rare diseases. The trend reflects news about the progress of clinical trials.
P/E of the market segment - Pharma neurology
This chart reflects the average valuation for the speculative biotech sector—a benchmark for Dyne. For investors, it serves as a benchmark, indicating the overall level of optimism. Against this backdrop, one can gauge expectations for Dyne's developments in treating rare muscle diseases and its drug delivery platform.
P/E of the market as a whole
Dyne Therapeutics develops drugs to treat rare muscle diseases using a platform designed to improve drug delivery to target tissues. This graph of overall investor risk appetite in biotech is vital for Dyne. It determines whether investors are willing to fund the company at an early stage based on the promise of its scientific platform.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Dyne Therapeutics Inc.
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. Its technology aims to improve drug delivery directly to muscle tissue. The company's valuation is based on expectations of success in clinical trials. This chart shows analysts' confidence in the potential of its scientific platform.
%20P%2FE%20Dyne%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Dyne-Therapeutics-Inc.&v=1772631877519 "Chart of the company's future (projected) P/E Dyne Therapeutics Inc.")
Future (projected) P/E of the market segment - Pharma neurology
Dyne Therapeutics is a biotech company developing therapies for rare muscle diseases. Its valuation relative to other biotechs reflects expectations for its innovative platform, which delivers drugs directly to muscle tissue. This is a bet by investors that its approach will be more effective than its competitors'.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-neurology&v=1772631877543 "Future (projected) P/E graph of the market segment - Pharma neurology")
Future (projected) P/E of the market as a whole
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. Its platform aims to deliver drugs directly to muscle tissue. This chart shows investors' overall risk appetite. For biotechs with breakthrough but unproven technologies, a positive market environment makes it easier to raise capital.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772631877560 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Dyne Therapeutics Inc.
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. Its financial results, reflected here, reflect its investment in its unique FORCE platform, which delivers drugs directly to muscle tissue. Clinical success will determine its future.
Profit of companies in the market segment - Pharma neurology
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. This chart reflects the financial health of the neuroscience and muscle biotech segments. It demonstrates how close this complex field of medicine is to developing effective and commercially viable treatments.
Overall market profit
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. Its platform aims to improve drug delivery directly to muscle tissue. The company's value is determined by progress in clinical trials. The macroeconomic situation, reflected in this chart, is of secondary importance for DYN.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Dyne Therapeutics Inc.
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. Its innovative platform aims to deliver drugs directly to muscle tissue. The company's future revenue projections represent a long-term bet on the success of this technology and its clinical candidates, as assessed by analysts in this chart.
%20profit%20of%20the%20company%20Dyne%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Dyne-Therapeutics-Inc.&v=1772631877723 "Graph of future (projected) profit of the company Dyne Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Pharma neurology
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. Their FORCE™ platform combines antibodies with small interfering RNA to deliver drugs precisely to muscle tissue. This graph shows forecasts for the neurological segment, illustrating the high hopes placed on new approaches to treating genetic diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-neurology&v=1772631877750 "Graph of future (predicted) profits of companies in a market segment - Pharma neurology")
Future (predicted) profit of the market as a whole
Dyne Therapeutics, Inc. is a biotech company developing treatments for rare muscle diseases. This projected profit curve impacts the investment climate. Market optimism and economic growth are driving capital flows into the biotech sector, allowing companies like Dyne to fund their breakthrough, yet capital-intensive, research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772631877785 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Dyne Therapeutics Inc.
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. Without commercial revenue, its valuation, as shown in this chart, is based solely on investors' faith in its scientific platform and future commercial success.
P/S market segment - Pharma neurology
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. This chart shows the average valuation in the pharmaceutical and neuroscience sectors. It reflects investor expectations for Dyne's innovative platform, which combines antibodies with small interfering RNA (siRNA) for precise drug delivery to muscle tissue.
P/S of the market as a whole
Dyne Therapeutics, Inc. is a biotech company developing drugs to treat rare muscle diseases. Its FORCE platform aims to deliver drugs directly to muscle tissue. Future revenue depends on the success of this technology. This chart provides investors with a common framework for assessing the risks and potential of biotech.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Dyne Therapeutics Inc.
Dyne Therapeutics is a biotech company developing therapies for rare muscle diseases. Its valuation is based on the future potential of its FORCE platform. The chart reflects investors' belief that the company's technology will enable effective drug delivery to muscle tissue and the development of breakthrough treatments.
%20P%2FS%20Dyne%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Dyne-Therapeutics-Inc.&v=1772631877931 "The graph of the company's future (projected) P/S Dyne Therapeutics Inc.")
Future (projected) P/S of the market segment - Pharma neurology
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. Its FORCE™ platform enables drug delivery directly to muscle tissue. This chart shows how investors view the potential of this innovative technology compared to other companies working in the rare disease field.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-neurology&v=1772631877959 "Future (projected) P/S market segment graph - Pharma neurology")
Future (projected) P/S of the market as a whole
This chart reflects expectations for the biotech sector. For Dyne Therapeutics, a company developing therapies for rare muscle diseases, it's an indicator of investor appetite for innovation. Market optimism allows investors to attract capital for the development of complex drugs capable of delivering therapeutic agents directly to muscle tissue.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772631877997 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Dyne Therapeutics Inc.
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. Its FORCE™ platform enables drug delivery directly to muscle tissue. This chart reflects revenue from the partnership. In the future, it will show revenue from sales of targeted drugs targeting the genetic causes of muscular dystrophies.
Sales of companies in the market segment - Pharma neurology
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. This chart shows growth in the neurological pharmaceutical sector. Dyne's platform enables the delivery of therapeutic molecules directly to muscle tissue, which could be a breakthrough in the treatment of diseases such as myotonic dystrophy.
Overall market sales
Dyne Therapeutics, Inc. is a biotech company developing treatments for rare muscle diseases. Its value and prospects depend on the success of clinical trials. The overall economic environment, shown in this chart, influences investors' risk appetite and their willingness to fund long-term biotech research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Dyne Therapeutics Inc.
Dyne Therapeutics is a biotech company developing therapies for rare muscle diseases. Its platform focuses on precise drug delivery to muscle tissue. Future success depends on clinical trial results. This chart reflects analysts' confidence in the company's scientific approach and the commercial potential of its drugs if successful.
%20sales%20of%20the%20company%20Dyne%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Dyne-Therapeutics-Inc.&v=1772631878115 "Schedule of future (projected) sales of the company Dyne Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Pharma neurology
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. This forecast highlights expectations for the neuroscience segment of the pharmaceutical industry. It reflects the potential for developing new treatments for patients with severe genetic diseases, where Dyne is striving to achieve breakthroughs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-neurology&v=1772631878135 "Schedule of future (projected) sales of companies in the market segment - Pharma neurology")
Future (projected) sales of the market as a whole
Dyne Therapeutics, Inc. is a biotech company developing therapies for serious muscle diseases. Its valuation is based on the potential of its scientific platform and clinical candidates. The overall economic environment, reflected in this chart, influences the availability of capital for the biotech sector, which is necessary for conducting lengthy and expensive research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772631878182 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Dyne Therapeutics Inc.
Dyne Therapeutics develops innovative drugs to treat rare muscle diseases. This chart shows the financial picture of a company at the forefront of science. Negative values represent investments in clinical trials of its unique platform, which is designed to deliver drugs directly to muscle tissue.
Market segment marginality - Pharma neurology
Dyne Therapeutics is a biotech company developing drugs to treat serious muscle diseases. Its FORCE platform is designed to deliver drugs directly to muscle tissue. Its financial metrics reflect the R&D stage. This chart provides an overview of the company's operating model compared to other companies in the gene and RNA therapy field.
Market marginality as a whole
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. This overall market profitability chart is irrelevant to the company. Its future success depends entirely on the results of clinical trials and the ability of its platform to deliver drugs directly to muscle tissue, solving previously intractable medical problems.
Employees in the company, segment and market as a whole
Number of employees in the company Dyne Therapeutics Inc.
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. The chart shows its growing team of scientists and clinicians. This growth directly reflects the progress in preclinical and clinical trials of their innovative platform.
Share of the company's employees Dyne Therapeutics Inc. within the market segment - Pharma neurology
Dyne Therapeutics is developing therapies for rare muscle diseases using its FORCE platform for drug delivery to muscle tissue. This chart shows the percentage of leading biologists and chemists specializing in muscular dystrophies and antibody conjugation that the company employs. It reflects its concentration of unique scientific expertise to solve complex medical problems.
Number of employees in the market segment - Pharma neurology
Dyne Therapeutics, Inc. is a biotechnology company developing muscle-targeted therapies for the treatment of serious muscle diseases. Its FORCE platform combines antibodies with small interfering RNA (siRNA) for precise drug delivery to muscle tissue. This chart reflects the work in cutting-edge neurological pharmaceuticals, showing how new drug delivery platforms are opening up opportunities to treat rare diseases.
Number of employees in the market as a whole
Dyne Therapeutics is a biotechnology company developing treatments for rare muscle diseases. Their innovative platform addresses problems previously considered intractable. It exemplifies how science creates new opportunities and shapes an advanced economic sector, attracting the best minds and creating the jobs of the future.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Dyne Therapeutics Inc. (DYN)
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. This chart shows the valuation of this innovative platform. The astronomical market capitalization per employee suggests that the market is pricing in the potential of their technology for delivering drugs directly to muscle tissue.
%20of%20the%20company%20Dyne%20Therapeutics%20Inc.%20(DYN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Dyne-Therapeutics-Inc.-DYN&v=1772631878437 "Chart of market capitalization per employee (in thousands of dollars) of the company Dyne Therapeutics Inc. (DYN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma neurology
Dyne Therapeutics (DYN) is a biotech company developing the FORCE platform for muscle drug delivery to treat rare muscle diseases. This chart shows the industry average cost per employee. It helps assess the premium the market places on their scientific platform and R&D portfolio, based on their small staff of scientists.
%20by%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-neurology&v=1772631878451 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma neurology")
Market capitalization per employee (in thousands of dollars) for the overall market
Dyne Therapeutics, Inc. is a biotechnology company developing therapies for serious muscle diseases. This chart shows the average market value per employee, highlighting the company's high valuation of its scientific potential in the field of rare diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772631878461 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Dyne Therapeutics Inc. (DYN)
Dyne Therapeutics is a biotech company developing therapies for rare muscle diseases. These are currently in the clinical stage. This chart shows the company's per-employee loss. It reflects how much the company burns through each scientist and physician during the development and testing of its drug candidates.
%20Chart%20Dyne%20Therapeutics%20Inc.%20(DYN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Dyne-Therapeutics-Inc.-DYN&v=1772631878476 "Company Profit Per Employee (in thousands of dollars) Chart Dyne Therapeutics Inc. (DYN)")
Profit per employee (in thousands of dollars) in the market segment - Pharma neurology
Dyne Therapeutics (DYN) is an R&D biotech (muscle diseases). This chart shows the benchmark for "Pharma" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of money in the hopes of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-neurology&v=1772631878494 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma neurology")
Profit per employee (in thousands of dollars) for the market as a whole
Dyne Therapeutics is a biotech company developing treatments for muscular dystrophies. Their platform (FORCE) aims to deliver drugs directly to muscle. They are an early-stage R&D company. The graph shows the loss per employee—the "burn rate" of capital spent on preclinical and early clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772631878529 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Dyne Therapeutics Inc. (DYN)
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. For a company in clinical development, this graph is an indicator of future potential. It illustrates how a single successful drug can generate colossal revenue for a small team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Dyne-Therapeutics-Inc.-DYN&v=1772631878547 "Sales chart per company employee Dyne Therapeutics Inc. (DYN)")
Sales per employee in the market segment - Pharma neurology
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. The company is in clinical R&D. This chart shows the average revenue per employee in this segment. It serves as a productivity benchmark for commercial pharmaceutical companies and helps evaluate the effectiveness of Dyne's scientific team.
Sales per employee for the market as a whole
Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for rare muscle diseases. The company has no commercial products and, therefore, no revenue from them. This metric is currently irrelevant. The company's entire value lies in its R&D platform and the potential of its scientific team.
Short shares by company, segment and market as a whole
Shares shorted by company Dyne Therapeutics Inc. (DYN)
Dyne Therapeutics develops drugs to treat rare muscle diseases. The company uses its platform to deliver drugs directly to muscle tissue. This is early-stage biotech. This chart shows the proportion of skeptics who bet the technology won't work in humans or that clinical trials will fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Dyne-Therapeutics-Inc.-DYN&v=1772631878603 "Short Shares Chart for the Company Dyne Therapeutics Inc. (DYN)")
Shares shorted by market segment - Pharma neurology
Dyne Therapeutics, Inc. is a biotech company developing drugs to treat rare muscle diseases. Their platform (FORCE) aims to deliver drugs directly to muscle tissue. This chart shows the overall short position in the neuroscience/myology-focused biotech sector. Its rise reflects extreme investor skepticism regarding the success of clinical trials in this complex area.
Shares shorted by the overall market
Dyne Therapeutics (DYN) is a clinical-stage biotech focused on muscle diseases. This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives DYN of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Dyne Therapeutics Inc. (DYN)
Dyne Therapeutics is a biotech company developing treatments for rare muscle diseases. Stocks of preclinical and early clinical stage companies are pure bets on science. This chart measures the strength of investor faith in their platform. It shows when hopes (overbought) or doubts (oversold) regarding trial data peak.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Dyne-Therapeutics-Inc.-DYN&v=1772631878740 "RSI 14 indicator chart for the company's stock Dyne Therapeutics Inc. (DYN)")
RSI 14 Market Segment - Pharma neurology
Dyne Therapeutics is a biotech company developing the FORCE platform for muscle drug delivery. Their goal is to treat rare muscle diseases such as myotonic dystrophy. This chart reflects the overall sentiment in the biotech sector. It helps assess how the market views this speculative industry as a whole, and how Dyne compares to that.
RSI 14 for the overall market
Dyne Therapeutics (DYN) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast DYN (Dyne Therapeutics Inc.)
Dyne Therapeutics (DYN) is a biotech company developing drugs to treat rare muscle diseases. This chart shows the average target price. It reflects analysts' opinions on the potential of their scientific platform and early clinical data, which are critical for estimating future valuation.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-DYN-Dyne-Therapeutics-Inc.&v=1772631878846 "A chart showing analyst consensus forecasts for the expected stock price. DYN (Dyne Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price DYN (Dyne Therapeutics Inc.)
Dyne Therapeutics is a biotech company developing therapies for rare muscle diseases. Its signature product is the FORCE platform, which delivers drugs directly to muscle. This chart shows the difference between the consensus estimate and the price. It reflects analysts' confidence in this high-risk R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-DYN-Dyne-Therapeutics-Inc.&v=1772631878859 "A chart showing the difference between the consensus forecast and the actual stock price. DYN (Dyne Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma neurology
Dyne Therapeutics is a biotech company developing targeted therapies for serious muscle diseases (such as myotonic dystrophy) using its FORCE platform. This chart shows general expectations for the neuroscience sector, reflecting experts' confidence in the platform's ability to deliver drugs directly to muscle.
Analysts' consensus forecast for the overall market share price
Dyne Therapeutics is a biotech company developing drugs to treat rare muscle diseases. Their technology (FORCE) aims to deliver drugs directly to muscle tissue. This chart shows the overall risk appetite. For Dyne, as a clinical-stage company, overall market optimism is critical to raising the capital needed to complete expensive research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Dyne Therapeutics Inc.
Dyne Therapeutics is a biotech company developing drugs to treat rare muscular dystrophies. Their signature platform is the FORCE platform, which attaches a drug (RNAi) to an antibody for precise delivery to muscle tissue. This chart evaluates their scientific platform. It reflects investor expectations for clinical data and their ability to address the complex challenge of drug delivery to muscle tissue.
AKIMA Market Segment Index - Pharma neurology
Dyne Therapeutics (DYN) is a clinical-stage biotech and a pioneer in the treatment of muscle diseases. The company is developing the FORCE platform, which delivers drugs (like a Trojan horse) directly to muscle. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this innovative delivery platform (Dyne) differentiate it from the average pharma company?
The AKIM Index for the overall market
Dyne Therapeutics is a biotech company developing oligonucleotide drugs for the treatment of genetic muscle diseases (Duchenne muscular dystrophy). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this innovative scientific story, fueled by trial data, compares to the overall economic trends affecting biotech.
